​Targeted breast cancer pill capivasertib (Truqap) approved for use by NHS

  • 11 April 2025

Capivasertib (Truqap), developed by AstraZeneca, has been approved for NHS use in England and Wales to treat HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN mutations.

Over the shoulder shot of breast cancer imaging shown on a computer monitor

Truqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited). 

This twice-daily pill, combined with fulvestrant, extends progression-free survival from 3.1 to 7.3 months.

Approximately 3,000 women annually could benefit. The approval follows a reversal by NICE, with advocacy from Breast Cancer Now emphasizing the need for prompt genetic testing and faster drug approvals.

Read more here.